Drawing for STEBFYBA

USPTO serial 88226528

STEBFYBA

Reviewed by CopyMark Law Group

Reg. 5987587Status 710
Filing date
Status date
Registration date
Feb 18, 2020
Examiner
JACKSON, SHA-KARA ELOUISE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with STEBFYBA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Anthony P. Venturino

Anthony P. Venturino Vorys, Sater, Seymour and Pease LLPIPLAW@VORYS -PO BOX 2255Columbus, OH 43216-2255UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the treatment of pain, cardiovascular disorders, alimentary tract and metabolism problems, respiratory diseases, endocrine, musculoskeletal, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmological, otologicals, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue; anti-inflammatory and anti-rheumatics drugs; pharmaceutical preparations, namely, immunomodulators; pharmaceutical preparations, namely, hematological agents being pharmaceuticals for the treatment of hematological diseases; Enzyme replacement therapy preparations; Enzyme replacement therapy products, namely, infusions, liquids, tablets and powders for human use in the treatment of genetic disorders for medical purposes; Therapeutic cellular and stem cell compositions for medical useSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 28, 2026C8..CANCELLED SEC. 8 (6-YR)—
Feb 18, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Feb 18, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 14, 2020DP1B1(B) BASIS DELETED; PROCEED TO REGISTRATION—
Jan 13, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 10, 2019IUCNNOTICE OF ALLOWANCE CANCELLED—
Dec 10, 2019EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Jul 16, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 21, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 21, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 1, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 12, 2019ALIEASSIGNED TO LIE—
Mar 21, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 14, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Mar 14, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 14, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 14, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 11, 2019DOCKASSIGNED TO EXAMINER—
Jan 4, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 15, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance